Rationale for cholesteryl ester transfer protein inhibition
Current Opinion in Lipidology, 08/03/2012
Hewing B et al. – The two ongoing outcome trials, dal–OUTCOMES (dalcetrapib) and REVEAL (anacetrapib), will provide more conclusive answers for the concept of reducing cardiovascular risk by raising HDL cholesterol (HDL–C) with cholesteryl ester transfer protein inhibition.



